Seer (SEER)
(Delayed Data from NSDQ)
$1.78 USD
+0.01 (0.56%)
Updated Aug 6, 2024 03:59 PM ET
After-Market: $1.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
SEER 1.78 +0.01(0.56%)
Will SEER be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SEER based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SEER
Seer, Inc. (SEER) Reports Q1 Loss, Misses Revenue Estimates
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
SEER: What are Zacks experts saying now?
Zacks Private Portfolio Services
Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
Here's Why Seer, Inc. (SEER) Could be Great Choice for a Bottom Fisher
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
Other News for SEER
Seer to Report Second Quarter 2024 Financial Results on August 8, 2024
Seer Proteograph? Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
Seer announces publications highlighting studies on Proteograph Product Suite
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ?s Early Cancer Detection Study
Lab Instrument Industry Update - New Commercial Entrants